Patent US4155907A successfully refreshed from Google Patents.
US4155907A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for inhibiting ADP-induced platelet aggregation using phenylthioalkylamines
Assignee: Dow Chemical Co
•
Filing: 1976-08-16
•
Granted: 1979-05-22
•
Expires: 1996-08-16
Abstract
Abstract A method for inhibiting blood platelet aggregation in a mammal by administering internally to the mammal an effective amount of a phenylthio(sulfinyl or sulfonyl)alkylamine compound or a pharmaceutically-acceptable salt thereof.
Inventors
- 👤 Joseph E. Dunbar
- 👤 Louis E. Begin
- 👤 Robert J. Broersma
- 👤 George D. Dickerson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 00:43
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/08; C07D295/084; C07D295/088
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
158 words
A method for inhibiting ADP-induced platelet aggregation and treating thrombosis in a mammal comprising administering internally to said mammal a platelet aggregation inhibiting amount of a compound corresponding to the formula: ##STR3## or the pharmaceutically-acceptable salts thereof wherein: R 1 is diloweralkylamino, dicycloalkylamino, or cycloimino; R 2 is lower alkyl, morpholinyl, 4-morpholinylmethyl, or hydrogen with the proviso that when R 2 is alkyl or hydrogen, R 1 must be morpholinyl; R 3 is hydrogen, lower alkyl, halo, hydroxy, amino, acetamino, acetoxy, lower alkoxy, or carboxy; r is an integer of from 0 to 5; x is an integer of from 0 to 2; y is an integer of from 0 to 4 with the proviso that when R 2 is lower alkyl or morpholino, y is 1, and when R 2 is 4-morpholinylmethyl, y is 0; and z is an integer of from 0 to 3 with the proviso that when R 2 is hydrogen z is 0.
Claim 2
Independent Claim
158 words
A method for inhibiting ADP-induced platelet aggregation and treating thrombosis in a mammal comprising administering internally to said mammal a platelet aggregation inhibiting amount of a compound corresponding to the formula: ##STR3## or the pharmaceutically-acceptable salts thereof wherein: R 1 is diloweralkylamino, dicycloalkylamino, or cycloimino; R 2 is lower alkyl, morpholinyl, 4-morpholinylmethyl, or hydrogen with the proviso that when R 2 is alkyl or hydrogen, R 1 must be morpholinyl; R 3 is hydrogen, lower alkyl, halo, hydroxy, amino, acetamino, acetoxy, lower alkoxy, or carboxy; r is an integer of from 0 to 5; x is an integer of from 0 to 2; y is an integer of from 0 to 4 with the proviso that when R 2 is lower alkyl or morpholino, y is 1, and when R 2 is 4-morpholinylmethyl, y is 0; and z is an integer of from 0 to 3 with the proviso that when R 2 is hydrogen z is 0.
Claim 3
Dependent Claim
22 words
The method of claim 1 wherein R 1 of the compound is dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, dicyclohexylamino, piperidino, hexamethyleneimino, or morpholinyl.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein R 3 of the compound is lower alkyl, lower alkoxy, and hydroxy.
Claim 5
Dependent Claim
9 words
The method of claim 1 wherein x is 2.
Claim 6
Dependent Claim
10 words
The method of claim 2 wherein R 1 is morpholinyl.
Claim 7
Dependent Claim
16 words
The method of claim 5 wherein the compound is 4-(3-(4-hydroxyphenylsulfonyl)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 8
Dependent Claim
16 words
The method of claim 5 wherein the compound is 4-(3-(4-hydroxyphenylsulfonyl)-2-methylpropyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 9
Dependent Claim
18 words
The method of claim 1 wherein the compound is 2-(4-morpholinyl)ethyl p-tolyl sulfide and the pharmaceutically acceptable salts thereof.
Claim 10
Dependent Claim
18 words
The method of claim 1 wherein the compound is 4-fluorophenyl 2-(4-morpholinyl)ethyl sulfide and the pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim
18 words
The method of claim 1 wherein the compound is 2-(4-morpholinyl)ethyl pentafluorophenyl sulfide and the pharmaceutically acceptable salts thereof.
Claim 12
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(2-(4-fluorophenylsulfonyl)ethyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(2-(p-tolylsulfonyl)ethyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 14
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(3-(4-methoxyphenylsulfonyl)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 15
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(3-phenylsulfonyl)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 16
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(3-(2-aminophenylthio)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 17
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(5-(p-tolysulfonyl)pentyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 18
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(2-(phenylthio)ethyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 19
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(3-(p-tolysulfonyl)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 20
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(2-(3,4-dichlorophenylthio)ethyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 21
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(2-(4-methoxyphenylsulfonyl)ethyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 22
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4,4'-((1-phenylthio)methyl)-1,2-ethanediyl)-bis-morpholine and the pharmaceutically acceptable salts thereof.
Claim 23
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4,4'-(1-(((4-methylphenyl)sulfonyl)methyl)-1,2-ethanediyl)-bis-morpholine and the pharmaceutically acceptable salts thereof.
Claim 24
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4,4'-(1-(((4-methoxyphenyl)thio)methyl)-1,2-ethanediyl)-bis-morpholine and the pharmaceutically acceptable salts thereof.
Claim 25
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4,4'-(1-(((4-methoxyphenyl)sulfonyl)methyl)-1,2-ethanediyl)-bis-morpholine and the pharmaceutically acceptable salts thereof.
Claim 26
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(3-(4-aminophenylthio)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 27
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(3-(4-bromophenylthio)propyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 28
Dependent Claim
15 words
The method of claim 1 wherein the compound is 4-(3-(4-bromophenylsulfonyl)propyl)morpholine and the pharmaceutically-acceptable salts thereof.
Claim 29
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4,4'-(2-(phenylthio)-1,3-propanediyl)-bis-morpholine and the pharmaceutically acceptable salts thereof.
Claim 30
Dependent Claim
15 words
The method of claim 1 wherein the compound is 4,4'-(2-(phenylsulfonyl)-1,3-propanediyl)-bis-morpholine and the pharmaceutically-acceptable salts thereof.
Claim 31
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4,4'-(2-((4-methoxyphenyl)sulfonyl)1,3-propanediyl)-bis-morpholine and the pharmaceutically acceptable salts thereof.
Claim 32
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(4-(4-hydroxyphenylthio)butyl)morpholine and the pharmaceutically acceptable salts thereof.
Claim 33
Dependent Claim
16 words
The method of claim 1 wherein the compound is 4-(5-(4-hydroxyphenylthio)pentyl)morpholine and the pharmaceutically acceptable salts thereof.
References Cited (Backward Citations)
US3746768A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1982-05-21 | 1982-11-20 | 1983-05-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1986-05-21 | 1986-11-20 | 1987-05-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1990-05-21 | 1990-11-20 | 1991-05-22 | $7700.00 | Window Closed / Lapsed |